Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study
SG showed modest activity after EV in heavily pretreated patients with aUC. ORR with SG after EV was lower than reported in phase 2 and phase 3 clinical trials for SG in the postplatinum/ICI setting.
Authors
- Omar Alhalabi (ORCID: https://orcid.org/0000-0002-9658-2206)
- Matthew T. Campbell (ORCID: https://orcid.org/0000-0003-1915-4491)
- Irene Tsung (ORCID: https://orcid.org/0000-0002-9105-8659)
- Cindy Jiang (ORCID: https://orcid.org/0000-0002-2459-1875)
- Ali Raza Khaki (ORCID: https://orcid.org/0000-0002-4655-4426)
- Arnab Basu (ORCID: https://orcid.org/0000-0002-8678-3880)
- Albert Jang (ORCID: https://orcid.org/0000-0002-0461-6174)
- Hamid Emamekhoo (ORCID: https://orcid.org/0000-0002-8506-8703)
- Petros D. Grivas (ORCID: https://orcid.org/0000-0003-3965-3394)
- Vadim S. Koshkin (ORCID: https://orcid.org/0000-0003-2277-8668)
- Rafee Talukder (ORCID: https://orcid.org/0000-0002-6619-2573)
- Ajjai Alva (ORCID: https://orcid.org/0000-0002-1898-3522)
- Dory Freeman (ORCID: https://orcid.org/0000-0003-2617-0641)
- Tanya Jindal (ORCID: https://orcid.org/0000-0001-5954-3278)
- Deepak Kilari (ORCID: https://orcid.org/0000-0002-6999-1901)
- Jason Robert Brown (ORCID: https://orcid.org/0000-0001-6225-7555)
- I. Epstein
- Charles B. Nguyen (ORCID: https://orcid.org/0000-0002-1898-5501)
- Matthew P. Davidsohn (ORCID: https://orcid.org/0009-0000-1480-9423)
- Amanda Nizam (ORCID: https://orcid.org/0000-0001-5181-490X)
- Amy K. Taylor (ORCID: https://orcid.org/0000-0003-4559-4159)
- Joaquim Bellmunt (ORCID: https://orcid.org/0000-0003-2328-3421)
- Abhishek Tripathi (ORCID: https://orcid.org/0000-0002-5198-0673)
- Sumit Shah (ORCID: https://orcid.org/0000-0001-9479-2333)
- Dimitra Rafailia Bakaloudi (ORCID: https://orcid.org/0000-0002-1214-7507)
- Cameron Pywell
- Nancy B. Davis (ORCID: https://orcid.org/0000-0002-7933-2280)
- Salvador Jaime‐Casas (ORCID: https://orcid.org/0009-0009-4334-1300)
- Sean T. Evans
- Eugene Oh (ORCID: https://orcid.org/0000-0003-4125-603X)
- Michael Glover (ORCID: https://orcid.org/0000-0002-9811-9004)
- Dongjun Shin
- Shilpa Gupta (ORCID: https://orcid.org/0000-0001-6494-5853)
- Mehmet Asim Bilen
- Emily Lemke
Institutions
- Froedtert Hospital (US)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- University of California, San Francisco (US)
- Vanderbilt University (US)
- University of Washington (US)
- University of Michigan (US)
- University of Alabama at Birmingham (US)
- Fred Hutch Cancer Center (US)
- University of Wisconsin Carbone Cancer Center (US)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
- Michigan Center for Translational Pathology (US)
- University Hospitals Seidman Cancer Center (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Vanderbilt-Ingram Cancer Center
- O'Neal Comprehensive Cancer Center
- Stanford University (US)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1016/j.urolonc.2025.09.025
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00